Drilldown: Medicines
Medicines > classes 
:
Analgesic or
Benzodiazepine or
[[:Category:Barbiturates|Barbiturate (parent compound)]]
:
Analgesic or
Benzodiazepine or
[[:Category:Barbiturates|Barbiturate (parent compound)]] Use the filters below to narrow your results.
generic:
brand:
None (14) ·
(multiple, generic dominant) (1) ·
Dalmane (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Dolophine (1) ·
Doral (1) ·
Duragesic (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Mogadon (1) ·
Mysoline (1) ·
Nubain (1) ·
Nucynta (1) ·
Onfi (1) ·
Opana (1) ·
ProSom (1) ·
Restoril (1) ·
Rohypnol (1) ·
Serax (1) ·
Stadol (1) ·
Suboxone (1) ·
Talwin (1) ·
Tranxene (1) ·
Versed (1) ·
Vicodin (1) ·
Xanax (1)
classes: (Click arrow to add another value)
mechanism:
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
'"`UNIQ--vote-00000013-QINU`"' Strong CYP3A4 induction via the phenobarbital metabolite produces many interactions (reduces oral contraceptives, warfarin, many psychotropics). Essential-tremor efficacy is the unique pharmacological selling point'"`UNIQ--ref-00000014-QINU`"'. (1)
uses:
starting dose:
preparations:
None (39) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) ·
Tablets 50, 250 mg (1)
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (39) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Substantial teratogenic signal (barbiturate class effects including neonatal withdrawal and hemorrhagic disease of newborn).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (39) ·
Schedule IV (US) (1) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] in US. '''Federally non-controlled despite being a barbiturate''', a paradoxical situation given that its primary active metabolite phenobarbital is Schedule IV'"`UNIQ--ref-00000019-QINU`"' (1)
Showing below up to 42 results in range #1 to #42.